Robocath finalises creation of MicroPort JV through MedBot

Robocath, a company that designs, develops and commercialises cardiovascular robotic systems for the treatment of vascular diseases, has announced the creation of the joint venture with MicroPort Scientific Corporation (MicroPort), through ‘MedBot’, its MicroPort MedBot Co. Ltd subsidiary.

This strategic partnership will enable the commercialisation in China of its first robotic-assisted platform, R-One. Both companies will also carry out research and development activities as agreed. Robocath will hold 49% of this joint venture, 51% will be owned by MedBot.

This expansion will be facilitated by local manufacturing of consumables and robotic assembly to ensure optimal distribution of Robocath products in this market. The testing, clinical and regulatory activities required to receive National Medical Products Administration (NMPA) approval for R-One will begin immediately. Both companies will also carry out research and development activities related to the next long-distance generation of remote control over 5G network technologies and will develop artificial intelligence algorithms to be used with robotic-assisted platforms.

Philippe Bencteux, Chairman and Founder of Robocath, said: “We are excited to take this new step in our development which will permit us to rapidly penetrate the sector's leading market. We are impressed with the resources made available by our partner to fast-track the approval of our product in China.”

MedBot General Manager Dr Alex He added: “Since the announcement of our strategic partnership last April, we have strengthened our discussions with all of the Robocath team in order to establish this common structure which will undoubtedly ensure the commercial success of the R-One robotic-assisted platform in the Chinese market.”